Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update
Open Access
- 16 January 2020
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 101 (Suppl. 1), 2-15
- https://doi.org/10.1159/000504092
Abstract
Background: Patient care in ulcerative colitis (UC) remains challenging despite an array of established treatment options and emerging new therapies. The management of UC therapy should be guided by the endoscopic extent of inflammation, disease severity, and prognostic factors of poor outcome. Complete remission, defined as durable symptomatic and endoscopic remission without corticosteroid therapy, is the desired treatment goal. Summary: This review focuses on treatment recommendations for different clinical scenarios in moderate-to-severe UC: Active UC of any extent not responding to aminosalicylates, steroid-dependent UC, steroid-refractory UC, immunomodulator-refractory UC, and acute severe UC. Comprehensive treatment algorithms for daily clinical practice were developed based on published guidelines and current literature. Key Messages: While current treatment options including a number of biologicals and small molecules have evolved UC treatment to achieve sustained remission in a majority of patients, upcoming treatment options with different molecular pathways and different modes of actions will further increase the need for personalized medicine.Keywords
This publication has 97 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyGut, 2013
- Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitisEmergencias, 2010
- Drug Monitoring in Inflammatory Bowel Disease: Helpful or Dispensable?Digestive Diseases, 2009
- Infliximab Rescue Therapy after Cyclosporin Failure in Steroid-Refractory Ulcerative ColitisDigestion, 2009
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scandinavian Journal of Gastroenterology, 2009
- Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trialGut, 2008
- Tacrolimus (FK506) for induction of remission in refractory ulcerative colitisEmergencias, 2008
- The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohortAlimentary Pharmacology & Therapeutics, 2006
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006